(Q33345245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Dynamics and potential impact of the immune response to chronic myelogenous leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Peter P Lee

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Doron Levy

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

20 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

PLOS Computational Biology

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

e1000095

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

9 January 2020

copyright license

start time

20 June 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Development and dynamics of robust T-cell responses to CML under imatinib treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Infectious complications of chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Dynamics of chronic myeloid leukaemia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Drug resistance in cancer: principles of emergence and prevention

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Chronic myelogenous leukaemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

21 June 2018

Chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2427197

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

21 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

Post-transplantation dynamics of the immune response to chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

Models of CD8+ responses: 1. What is the antigen-independent proliferation program

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

Different Dynamics of CD4+ and CD8+ T Cell Responses During and After Acute Lymphocytic Choriomeningitis Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

Minimal residual disease in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PCBI.1000095

10.1371/JOURNAL.PCBI.1000095

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

DBLP publication ID

journals/ploscb/KimLL08

1 reference

DBLP Dataset 2021-01-02

28 January 2021

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18566683%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

PubMed publication ID

18566683

1 reference